This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -50% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AlerisLife (ALR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Five Star (ALR) delivered earnings and revenue surprises of -15.79% and 0.76%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 8.76% and 5.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AlerisLife (ALR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Star (ALR) delivered earnings and revenue surprises of -33.33% and 4.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AlerisLife (ALR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Star (ALR) delivered earnings and revenue surprises of -181.82% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Are Options Traders Betting on a Big Move in Alere (ALR) Stock?
by Zacks Equity Research
Surging implied volatility makes Alere (ALR) Stock lucrative to the option traders.
Alere (ALR) Shows Strength: Stock Adds 15.9% in Session
by Zacks Equity Research
Alere Inc. (ALR) shares jumped almost 16% in the last trading session.
Strength Seen in Alere (ALR): Stock Adds 9.4% in Session
by Zacks Equity Research
Alere Inc. (ALR) shares rose over 9% in the last trading session.
Alere Forensic Toxicology Division Gets ABFT Accreditation
by Zacks Equity Research
Alere Inc. (ALR), a leading player in rapid diagnostic tests, announced that its forensic toxicology division has received accreditation from the American Board of Forensic Toxicology.
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege
by Zacks Equity Research
Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.